(AGENPARL) - Roma, 25 Aprile 2024 - (AGENPARL) – gio 25 aprile 2024 8.00 AM CEST / 25-Apr-2024 / Detection Technology Oyj (FNFI:DETEC)
Detection Technology Plc company announcement 25 April 2024 at 09:00 (EEST)
DETECTION TECHNOLOGY PLC BUSINESS REVIEW JANUARY-MARCH 2024
Detection Technology Q1 2024: Strong sales in Security, improved financial
performance
January-March 2024 highlights
· Net sales decreased by -0.2% to EUR 22.7 million (22.8)
· Net sales of Industrial Solutions Business Unit (IBU) increased by 5.3% to
EUR 3.6 (3.4)
· Net sales of Medical Business Unit (MBU) decreased by -20.9% to EUR 9.5
million (12.0)
· Net sales of Security Business Unit (SBU) increased by 31.5% to EUR 9.6
million (7.3)
· Operating profit (EBITA) was EUR 2.3 million (1.5)
· Operating margin (EBITA-%) was 10.0% of net sales (6.5%)
UNAUDITED (Figures in parentheses refer to the corresponding period of the
previous year.)
President and CEO, Hannu Martola:
“Q1 closed as we expected. Our overall year-on-year net sales remained stable
and our financial result improved. Our security application sales were
particularly strong, whereas sales in industrial applications were more modest
than expected. Medical sales, however, were weak. Our market shares remain
broadly unchanged.
The industrial market recovered towards the end of Q1; demand in the food sector
in particular showed positive signs of recovery. Nevertheless, the development
of sales in the food sector lagged behind our expectations due to customers’
stocks, which resulted in our industrial sales lagging behind target. This was
compensated by good development in TFT (thin-film transistor) flat panel
detector sales. We expect our industrial solution sales to head towards stronger
growth in Q2, thanks to improving demand in the food industry and our TFT
product portfolio.
The measures of the Chinese government to modernize its healthcare sector and
the related anticorruption campaign targeted at healthcare sector end operators,
along with fiercer price competition and turmoil in the global medical market,
curbed our medical sales more than we expected. We expect demand in medical
applications to remain muted in Q2 and expect a positive turn at the beginning
of Q3.
Our security application sales grew significantly in markets outside China, in
particular in Europe and India. The most important growth driver in terms of
applications was computed tomography (CT) applications for the aviation market.
In addition to aviation, the global security market is expected to grow this
year faster than previously expected. We anticipate annual market growth to be
around 8 percent in the medium term.
Our year-on-year result for Q1 improved, and cash flow turned positive. We are
this year making strong progress towards our operating margin target of 15
percent (EBITA). Improved productivity, sales mix, and growth in sales continue
to boost our result.
During the period, we decided to expand our business to India and recruited a
local director to develop our Indian business. India is about to make
significant investments in infrastructure, namely in the healthcare, traffic,
and manufacturing industries, and we want to be there to promote these projects.
Other important events in Q1 included the opening of our new premises in Oulu,
Finland. The project was completed according to our targets and production has
already been launched. We will gradually increase our production capacity for EU
-origin products.
In our view, the reform of Chinese healthcare sector and the related
anticorruption campaign will continue, and the global medical market in Q2 as
well as our sales will decrease. Growth will continue in our other main markets,
and both our security and industrial application sales will see double-digit
growth in Q2. We expect our year-on-year total net sales to remain stable in Q2
and turn to a growth path in Q3 for the rest of the year.”
Key figures
(EUR 1,000) 1-3/2024 1-3/2023 1-12/2023
Net sales 22,706 22,753 103,794
Change in net sales, % -0.2% 12.0% 5.3%
EBITA excluding NRI 2,263 1,477 9,656
EBITA excluding NRI, % 10.0% 6.5% 9.3%
Non-recurring items (NRI) 0 0 -873
EBITA 2,263 1,477 8,784
EBITA, % 10.0% 6.5% 8.5%
R&D costs 2,512 2,962 11,702
R&D costs, % of net sales 11.1% 13.0% 11.3%
Cash flow from operating 2,980 -485 9,672
activities
Net interest-bearing debt -14,508 -19,572 -12,665
at end of period
Return on investment (ROI), 11.2% 7.1% 9.9%
Gearing, % -20.3% -28.0% -17.4%
(diluted), EUR
Number of shares at the end 14,655,930 14,655,930 14,655,930
of the period
Weighted average number of 14,655,930 14,655,930 14,655,930
shares outstanding
Weighted average number of 14,655,930 14,669,582 14,660,912
shares outstanding, diluted
Development of net sales
Detection Technology expected its overall year-on-year net sales to remain
stable in Q1, which also materialized. Medical sales decreased significantly.
Sales in security applications shot up and sales in industrial applications
grew, too. Growth in other businesses was not, however, sufficient to create
positive overall growth. The company’s total net sales decreased by -0.2%
(12.0%) year-on-year, totalling EUR 22.7 million (22.8).
Recovery in the industrial market that started in the previous review period
continued; NDT (nondestructive testing) being a significant growth driver.
Demand in food industry applications showed signs of recovery, even though sales
in the segment remained below expectations due to customers’ stocks. As a
result, Detection Technology’s sales in industrial applications grew but lagged
behind expectations. The net sales of the Industrial Solutions Business Unit
(IBU) grew by 5.3% (-3.0%), totaling EUR 3.6 million (3.4) in Q1 of 2024. Growth
in net sales was mainly created by TFT flat panel detector sales in Asia. IBU
generated a total of 15.9% (15.0%) of the company’s total net sales.
The measures taken by the Chinese government to modernize its healthcare sector
and its anticorruption campaign targeted at healthcare end operators continued
in Q1, which further delayed purchasing processes. On the other hand, fiercer
price competition and turmoil in the global market also affected demand
dynamics. As a result, the net sales of the Medical Business Unit (MBU)
decreased by -20.9% (14.6%), totalling EUR 9.5 million (12.0) in Q1. MBU
generated a total of 42.0% (52.9%) of the company’s total net sales.
The net sales of the Security Business Unit (SBU) increased by 31.5% (16.2%)
year-on-year, totalling EUR 9.6 million (7.3) in Q1. Demand in security
applications increased in markets outside China, particularly in Europe and
India. The most important growth driver in sales was CT applications for the
aviation industry, but demand was also solid for line scanner applications. SBU
generated a total of 42.2% (32.0%) of the company’s total net sales.
The Asia-Pacific countries (APAC) accounted for the company’s largest
geographical market area in Q1 of 2024, with its 72.0% (68.5%) share. The share
of the net sales for Europe, Middle East and Africa (EMEA) was 24.0% (20.5%) and
Americas 4.0% (11.0%). The share of Americas fell below ten percent due to one
-timers. The share of net sales accounted for by Detection Technology’s top five
customers was 53.2% (51.6%) in Q1.
Strategy implementation
During the review period, Detection Technology made a strategically important
decision to expand its business to India. The company has recruited a local
director to develop the company’s business in India in a holistic manner.
India is expected to be one of the fastest growing global economies in the
coming years. India is about to make significant investments in infrastructure
such as the healthcare, traffic, and manufacturing industries in order to boost
economic growth. According to the government’s plans, more than 100 airports
will be built in India in the coming years.
Detection Technology completed its business premises project in Oulu, Finland,
within schedule and within the set budget. The operations were moved to the
premises and production was launched in Q1 of 2024. Production capacity in Oulu
will be increased to meet demand. The company has the capability to make 10
percent of its sales in Oulu by the end of the year. The company will expand its
production in Oulu in order to be able to offer a wider range of EU Origin
products and to minimize risks.
In the review period, the company has continued the development of TFT flat
panel detector solutions and their sales in the medical and industrial X-ray
imaging market. According to the company’s view, the new business will grow
faster than its legacy business.
Business outlook
Detection Technology expects its year-on-year total net sales to remain stable
in Q2 and turn to growth in Q3 of 2024.
Geopolitical situation, U.S.-China relations, global economy, inflation, the
measures taken in China to reform its healthcare, price competition especially
in China, the indirect impacts of the war in Ukraine, and events in the Middle
East create uncertainty.
Detection Technology aims to increase its sales by at least 10% per annum and to
achieve an operating margin (EBITA) of 15% in the medium term.
Half-yearly report 2024
Detection Technology will publish the half-yearly report on 6 August 2024.
Espoo, Finland 24 April 2024
Board of Directors, Detection Technology Plc
Further information
President and CEO Hannu Martola will be available for interviews and further
information on the release date at 9:00-11:00 (EEST).
Hannu Martola, President and CEO
Nordea is the company’s Certified Advisor under the Nasdaq First North GM rules,
Detection Technology is a global provider of X-ray detector solutions and
services for medical, security, and industrial applications. The company’s
solutions range from sensor components to optimized detector subsystems with
ASICs, electronics, mechanics, software, and algorithms. It has sites in
Finland, China, France, and the US. The company’s shares are listed on Nasdaq
First North Growth Market Finland under the ticker symbol DETEC.
Distribution: Nasdaq Helsinki, key media, www.deetee.com
If you would rather not receive future communications from Detection Technology Oyj, please go to https://optout.ne.cision.com/en/sBGodLrK7t8Baf11eQrVJBqiGApq1Ah3MWyc6Q1E1bUbRAMxT65zx2ESr7hzrXGZytP6o18PBBcBM4gm4LBKrg7Mnoe7RpWJ57Y5uU6wASr52.
Detection Technology Oyj, A Grid, Otakaari 5A, Espoo, 02150 Finland
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Detection Technology Oyj, please go to https://optout.ne.cision.com/en/sBGodLrK7t8Baf11eQrVJBqiGApq1Ah3MWyc6Q1E1bUbRAMxT65zx2ESr7hzrXGZytP6o18PBBcBM4gm4LBKrg7Mnoe7RpWJ57Y5uU6wASr52.
Detection Technology Oyj, A Grid, Otakaari 5A, Espoo, 02150 Finland
Trending
- FI: Craxi, Piemonte è straordinario bacino di dirigenti e consensi
- COMUNICATO STAMPA – Carabinieri: Battistoni (FI), riconoscenza per loro missione
- DE GENNARO, COSTA (FI): “LA MACELLERIA MEDIATICA HA FATTO UN’ALTRA VITTIMA
- Cortei: Miele (Lega), Andrea esempio di coraggio. Violenza non è libertà, difendere istituzioni è scelta di valore
- “Mia madre, mia figlia, mia sorella”, il programma di mercoledì 25 Incontro al PalaRinaldi sulle madri costituenti, “Amore e psiche” al museo
- Caso De Gennaro e Commissione Antimafia, Marinella Pacifico: «Tragico epilogo di un tentativo fallito di riscrivere la Storia. Resta il peso morale di cotanta spregiudicatezza»
- Dl Scuola: Costa, solo FI fa battaglie liberali, senza di noi non si vince
- Comunicato Stampa 2063/2026 Sanità. Il plauso del presidente Stefani per la prima donazione a cuore fermo all’Ospedale di Piove di Sacco (PD)
- DECRETO CORTEI, BONELLI (AVS): “DELMASTRO VUOLE TOGLIERE LE BORSE DI STUDIO AGLI STUDENTI INDAGATI? ALLORA SI TOLGA LO STIPENDIO A LUI, CHE È CONDANNATO
- Incontro pazienti-medici sui linfomi